What is the appropriate treatment for severe atopic dermatitis involving the groin, perianal area, and scalp in a 14‑year‑old boy?

Treatment Approach for Severe Atopic Dermatitis in Groin, Perianal, and Scalp Areas

For this 14-year-old boy with severe atopic dermatitis in sensitive areas (groin, perianal, scalp), start with low-to-medium potency topical corticosteroids (TCS) for acute flare control, then transition to topical calcineurin inhibitors (TCIs) for maintenance therapy in the groin and perianal areas to avoid skin atrophy, while considering wet-wrap therapy for 3-7 days if initial treatment fails, and escalate to dupilumab if refractory to topical treatments 1, 2.

Immediate Management Strategy

First-Line Topical Therapy

For sensitive areas (groin, perianal):

• Use low-to-medium potency TCS initially for flare control, but limit duration to avoid skin atrophy 1
• The groin, perianal area, and skin folds are highly sensitive areas where potent TCS must be used with extreme caution 1
• After achieving initial control, switch to TCIs (tacrolimus 0.1% or pimecrolimus 1%) for maintenance, as these are steroid-sparing and safe for sensitive areas 1

For scalp:

• Medium potency TCS can be used more liberally on the scalp compared to intertriginous areas
• Consider scalp-specific formulations (solutions, foams) for better penetration

Critical adjunct:

• Intensive emollients applied liberally and frequently—this has both short- and long-term steroid-sparing effects 1

Second-Line: Wet-Wrap Therapy

If conventional topical therapy fails after 1-2 weeks:

• Wet-wrap therapy with TCS for 3-7 days (maximum 14 days in severe cases) 1
• This is an effective short-term treatment for moderate-to-severe AD and should be considered before systemic therapy 1
• Promotes trans-epidermal penetration of TCS and serves as a barrier against scratching

Proactive Maintenance Strategy

Once acute flare is controlled:

• Twice-weekly application of TCS or TCIs to previously affected areas helps prevent relapses 1
• This proactive approach is specifically recommended for moderate-to-severe AD in children 1

Systemic Therapy Escalation

When to Escalate

If the patient fails adequate topical therapy (including wet-wraps) after 2-4 weeks, systemic therapy is warranted.

First-Line Systemic: Dupilumab

Dupilumab is the recommended first-line systemic therapy for severe-to-very severe AD refractory to topical treatment 1, 3, 2:

• FDA-approved biologic with strong evidence in pediatric populations
• Superior safety profile compared to traditional immunosuppressants
• Can be used long-term without the risks associated with cyclosporine or oral corticosteroids

Alternative Systemic Options

If dupilumab is unavailable or not tolerated:

• JAK inhibitors (upadacitinib, abrocitinib, baricitinib) are highly effective but carry significant risks and should be reserved for severe refractory cases 4, 3, 2
• Cyclosporine remains an option for very severe AD, adjusted to minimal effective dose once response is achieved 1
• Avoid long-term oral corticosteroids due to unfavorable risk-benefit profile 1

Adjunctive Measures

Infection Management

Assess for secondary bacterial infection:

• Groin and perianal areas are prone to bacterial colonization with Staphylococcus aureus
• If clinical signs of infection present: use systemic antibiotics (not topical, due to resistance risk) 1
• Consider intranasal mupirocin and bleach baths (0.005% sodium hypochlorite) to reduce bacterial burden 1
• Note: TCS and TCIs themselves reduce S. aureus colonization by improving barrier function 1

Symptom Control

• Oral antihistamines as adjuvant therapy for pruritus, particularly sedating antihistamines at night to improve sleep 1
• These don't directly treat AD but improve quality of life

Critical Pitfalls to Avoid

1. Do not use potent TCS long-term in groin/perianal areas—this will cause skin atrophy, striae, and potentially systemic absorption 1

2. Avoid topical antibiotics long-term—increases resistance and sensitization risk 1

3. Do not use systemic corticosteroids for chronic management—unfavorable risk-benefit profile in children 1

4. Phototherapy is not recommended for this 14-year-old—while he's technically old enough (>12 years), the long-term skin cancer risk in adolescents remains unclear, especially if he may need systemic immunosuppression later 1, 5

Treatment Algorithm Summary

1. Week 0-2: Low-medium potency TCS to all areas + intensive emollients + oral antihistamines for itch
2. Week 2-4: If inadequate response, add wet-wrap therapy for 3-7 days
3. Week 4+: Transition groin/perianal to TCIs for maintenance; continue TCS on scalp as needed
4. Ongoing: Proactive twice-weekly TCS/TCI to previously affected areas
5. If refractory: Escalate to dupilumab (or JAK inhibitor if dupilumab unavailable/not tolerated)

The location of this patient's disease (groin, perianal, scalp) requires particular attention to potency selection and duration of TCS use to balance efficacy with safety 1, 2.